Blotter

Election and pandemic complicate appropriations

Answers to questions you probably have about the process, including how the NIH will fare
Benjamin Corb
June 10, 2020

Even in what you might call normal times over the past 20 years, passing an annual appropriations package for the National Institutes of Health, National Science Foundation and other federal science funding agencies would be complicated.  Last year, the NIH’s budget was completed and approved before the start of the fiscal year, but that was fairly unusual. Most years have been defined by continuing resolutions, threats of government shutdowns and spending caps.

This year, the normal challenges of a difficult political process are exacerbated by two complications. First, it is a presidential election year — and the appropriations process historically stalls in election season, as the entire U.S. House of Representatives and one-third of the U.S. Senate are up for reelection. Second, the COVID-19 pandemic has changed how Congress operates. (It has already passed multiple emergency supplemental spending bills.) All this results in an appropriations season like we’ve never seen before.

To clarify the challenges and our expectations and hopes for appropriations season, below I've compiled a short list of questions and answers.

Are appropriations going to happen this year?

Yes. The federal budget is reset on an annual basis, and Congress has no mechanism that would allow it to automatically reload funding for federal agencies or to increase spending on important programs. At a minimum, Congress will have to pass a continuing resolution to temporarily keep funding at the current level.

Is there a chance that the NIH’s budget increases continue in FY2021?

Yes, there is a great chance that will happen. The NIH has been one of very few agencies to benefit from strong bipartisan and bicameral support, and that has resulted in billions of dollars in increases to the agency's budget over the past several years. Before and during the COVID-19 pandemic, Republican and Democratic leaders have signaled to advocates that increases are likely to continue into this next fiscal year.

Aren’t there spending caps that limit discretionary spending?

FY21 will be the final year of the 10-year stretch of the Budget Control Act, a law that established limits to federal spending. Last year, a two-year deal was reached to raise the spending caps for FY20 and FY21. The agreed-upon spending level for FY21 increases domestic discretionary spending by $5 billion over last year’s levels. That is not a big increase (less than 1%), but, as I said earlier, there are indications that some of that would go toward supporting the NIH.

How is COVID-19 pandemic funding affecting appropriations?

Trillions of dollars have been provided to the NIH in response to the pandemic, with a focus on increasing testing capacity, vaccine development, and basic research into the SARS-COV-2 virus. That funding is specifically marked for COVID-19 research, and most of it has a 2024 expiration date. Appropriators have been clear that, while pandemic response and research on SARS-COV-2 is critically important at this time, they respect and understand the important work done by the NIH under normal circumstances. Accordingly, all indications point to an appropriations process that respects the emergency funding but does not allow the NIH's baseline appropriation to be affected going forward.

What comes next in the process?

Appropriations committees have held hearings on NIH funding, and the House appropriations committee has released an aggressive schedule for July. Nita Lowey, D-N.Y., who heads the appropriations committee, has announced that the appropriations subcommittees will markup bills in the first two weeks of July, and the full House will debate and vote on  12 appropriations bills before the end of July. This process is expected to be relatively partisan, with passage likely to happen with party-line votes. By comparison, the Senate has not released its schedule for the process. Congress has until Sept. 30 to pass spending bills or a continuing resolution.

Enjoy reading ASBMB Today?

Become a member to receive the print edition monthly and the digital edition weekly.

Learn more
Benjamin Corb

Benjamin Corb is the former director of public affairs at ASBMB.

Related articles

Gary Felsenfeld (1929–2024)
Michael M. Gottesman, Christopher Wanjek & Martin Gellert
Upcoming opportunities
ASBMB Today Staff

Get the latest from ASBMB Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in Policy

Policy highlights or most popular articles

Meet the 2024 ASBMB Advocacy Training Program delegates
Training

Meet the 2024 ASBMB Advocacy Training Program delegates

June 13, 2024

The program's sixth cohort will learn how to advocate for science funding and support this summer and will visit Capitol Hill in 2025.

NPA task force releases report on postdoc policies
News

NPA task force releases report on postdoc policies

June 12, 2024

The National Postdoctoral Association recommends institutions act in eight priority areas to improve the trainee experience.

ASBMB members advocate for basic science
News

ASBMB members advocate for basic science

May 30, 2024

In 65 meetings on Capitol Hill, scientists urged legislators to support budget increases for NIH, NSF and DOE.

A call to action: Urge Congress to support scientific research
Funding

A call to action: Urge Congress to support scientific research

May 21, 2024

ASBMB members can write to policymakers to advocate for robust science funding in fiscal year 2025.

ASBMB members head to Capitol Hill
Announcement

ASBMB members head to Capitol Hill

May 20, 2024

They will encourage lawmakers to support essential R&D appropriations to keep the U.S. competitive and retain highly skilled talent.

Genetics studies have a diversity problem that researchers struggle to fix
News

Genetics studies have a diversity problem that researchers struggle to fix

April 28, 2024

Researchers in South Carolina are trying to build a DNA database to better understand how genetics affects health risks. But they’re struggling to recruit enough Black participants.